



FOR IMMEDIATE RELEASE  
June 28, 2010

**SALIENT PHARMACEUTICALS  
ANNOUNCES EXPANSION OF SCIENTIFIC ADVISORY BOARD**

HOUSTON, Texas — Timothy D. Phillips, PhD, a professor at Texas A&M University and an internationally known expert in the world of food safety and mycotoxins, has joined Salient Pharmaceutical's Scientific Advisory Board.

Salient Pharmaceuticals Incorporated is a Texas-based, life sciences company developing a proprietary compound intended for use in treating severe diarrhea associated with chemotherapy, chronic conditions and infectious diseases. In Dr. Phillips, they have added to their scientific panel the world's leading expert in the use of the base compound behind Salient's CASAD™ product. Dr. Phillips has researched its use for years including a number of *in vitro* and *in vivo* studies, including critical human studies.

“We are working on a disease that affects millions of people around the world and we are excited to have the experience of Dr. Phillips on our Board,” said Richard Scruggs, President and CEO of Salient Pharmaceuticals. “His extensive research experience includes a number of very important human studies that will give us unique insight into the product's characteristics and capabilities.”

In 2009, Dr. Phillips was the recipient of the National Sigma Xi Award for Innovation. He has been the recipient of a number of grants from industry and government organizations including the National Institutes of Health (NIH) and United States Agency for International Development (USAID). He has authored or co-authored a number of white papers as well as presented before leading organizations such as the World Health Organization and the Center for Disease Control, on issues related to food safety, toxin mitigation and other critical issues.

Dr. Phillips is a Professor of Veterinary Integrative Biosciences at Texas A&M University and serves on the faculties of Toxicology and Food Science. He is also a member of the faculty at the Texas Tech University's Institute of Environmental and Human Health and the Texas A&M Health Science Center. Previously, Dr. Phillips has served as Director of the Center for Food Safety and Chair of the Faculty of Toxicology at Texas A&M University.

He joins Robert A. Newman, PhD and chair of Salient's Scientific Advisory Board; John G. Bartlett, MD and Professor of Medicine at Johns Hopkins; Al B. Benson, MD and Professor of Medicine at Northwestern University's Feinberg School of Medicine; Robert H. Carpenter, DVM and Chief Science Officer at Salient; H. Andrew Hansen II, MD at Central Texas Cardiovascular Surgery; William J. Sandborn, MD and Professor of Gastrointestinal Research at the Mayo Clinic; and Adam Zong, PhD and head of Hematology Portfolio at Bristol-Myers Squibb.

Formed in 2007, Salient Pharmaceuticals' mission is to improve health and quality of life while strengthening the odds of therapy success for patients who suffer from the debilitating effects of

chronic and/or acute diarrhea. Now the subject of multiple pre-clinical and clinical studies, Salient's proprietary lead compound is intended for use in treating severe diarrhea associated with chemotherapy, chronic conditions, infectious diseases and other drug therapies.

# # #

Contact: Mike Kolar  
Contact: 512-427-3117  
Email: Mike.kolar@kolarmail.com